Results 21 to 30 of about 848 (155)
The Silent Pandemic: Antifungal Resistance and the Future of Invasive Fungal Disease Management [PDF]
MicroorganismsInvasive fungal diseases (IFDs) represent an escalating global health threat, compounded by the rapid emergence of antifungal resistance (AFR). This review synthesizes the contemporary landscape of AFR from clinical and microbiological perspectives ...
Ruchika Bagga +1 more
doaj +2 more sources
JHLT OpenNon-Aspergillus molds, including Mucorales, Scedosporium, Lomentospora, and Fusarium species, are a significant cause of morbidity and mortality in heart and lung transplant recipients.
Emily M. Eichenberger, MD, MHS +2 more
doaj +2 more sources
Innovative antifungal strategies to combat drug-resistant Candida auris: recent advances and clinical implications [PDF]
Frontiers in Cellular and Infection MicrobiologyCandida auris is an invasive fungal pathogen recognized globally as a significant health threat due to its marked resistance to multiple classes of antifungal agents, including azoles, echinocandins, and polyenes.
Wei Du, Qihui Wang, Min Zhao
doaj +2 more sources
Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm [PDF]
DiagnosticsInvasive pulmonary aspergillosis (IPA), traditionally associated with severe immunosuppression and neutropenia, is increasingly reported among non-neutropenic patients.
Rocco Morena +3 more
doaj +2 more sources
Promising antimycotics for the treatment of invasive infections [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2023 This paper provides a review of the largest studies (over the period of 2018 to 2023) of promising novel antimycotics and their possible role in the treatment of invasive mycoses, including infections caused by resistant Candida and Aspergillus isolates.
Ortenberg E.А.
doaj +1 more source
Antifungal resistance, combinations and pipeline: oh my!
Drugs in Context, 2023 Invasive fungal infections are a strong contributor to healthcare costs, morbidity and mortality, especially amongst hospitalized patients. Historically, Candida was responsible for approximately 15% of all nosocomial bloodstream infections.
Kayla R Stover +4 more
doaj +1 more source
Calcineurin Inhibitors Synergize with Manogepix to Kill Diverse Human Fungal Pathogens
Journal of Fungi, 2022 Invasive fungal infections have mortality rates of 30–90%, depending on patient co-morbidities and the causative pathogen. The frequent emergence of drug resistance reduces the efficacy of currently approved treatment options, highlighting an urgent need
Sean D. Liston +4 more
doaj +1 more source
Microbiology Spectrum, 2022 We determined the susceptibility of South African Candida auris bloodstream surveillance isolates to manogepix, a novel antifungal, and several registered antifungal agents. C. auris isolates were submitted to a reference laboratory between 2016 and 2017.
Tsidiso G. Maphanga +3 more
doaj +1 more source
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
Journal of Fungi, 2022 The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel +5 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2021 : Objectives: : Manogepix, the active moiety of the prodrug fosmanogepix, is a novel antifungal with activity against major fungal pathogens including Candida (except Candida krusei), Aspergillus and difficult-to-treat/rare moulds.
Michael A. Pfaller +4 more
doaj +1 more source